Evidence map›Paper›PMID 33489468›Full record

ArticleOncoimmunology2021

Combined immune checkpoint blockade increases CD8+CD28+PD-1+ effector T cells and provides a therapeutic strategy for patients with neuroblastoma.

Soheila Shirinbak, Randall Y Chan, Shilpa Shahani, Sakunthala Muthugounder, Rebekah Kennedy, Long T Hung, G Esteban Fernandez, Michael D Hadjidaniel, Babak Moghimi, Michael A Sheard and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Neuroblastoma: an ongoing cold front for cancer immunotherapy.Journal for immunotherapy of cancer · 2023
    Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. miR-15a and miR-15b modulate natural killer and CD8Molecular therapy oncolytics · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Soheila ShirinbakDepartment of Pediatrics, Children's Hospital Los Angeles and the Saban Research Institute, Los Angeles, CA, USA.
Randall Y ChanDepartment of Pediatrics, Children's Hospital Los Angeles and the Saban Research Institute, Los Angeles, CA, USA.
Shilpa ShahaniCenter for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Sakunthala MuthugounderDepartment of Pediatrics, Children's Hospital Los Angeles and the Saban Research Institute, Los Angeles, CA, USA.
Rebekah KennedyDepartment of Pediatrics, Children's Hospital Los Angeles and the Saban Research Institute, Los Angeles, CA, USA.
Long T HungDepartment of Pediatrics, Children's Hospital Los Angeles and the Saban Research Institute, Los Angeles, CA, USA.
G Esteban FernandezDepartment of Pediatrics, Children's Hospital Los Angeles and the Saban Research Institute, Los Angeles, CA, USA.
Michael D HadjidanielDepartment of Pediatrics, Children's Hospital Los Angeles and the Saban Research Institute, Los Angeles, CA, USA.
Babak MoghimiDepartment of Pediatrics, Children's Hospital Los Angeles and the Saban Research Institute, Los Angeles, CA, USA.
Michael A SheardDepartment of Pediatrics, Children's Hospital Los Angeles and the Saban Research Institute, Los Angeles, CA, USA.
Alan L EpsteinKeck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Muller FabbriCancer Biology Program, University of Hawaii Cancer Center, Honolulu, HI, USA.
Hiroyuki ShimadaDepartment of Pediatrics, Children's Hospital Los Angeles and the Saban Research Institute, Los Angeles, CA, USA.
Shahab AsgharzadehDepartment of Pediatrics, Children's Hospital Los Angeles and the Saban Research Institute, Los Angeles, CA, USA.
Children's Hospital of Los Angeles · USUniversity of Southern California · USCenter for Cancer Research · USSouthern California University for Professional Studies · USUniversity of Hawaii Cancer Center

Funding

COG FOREIGN ACCRUALU10CA098543 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI ADAMSON, PETER C. · 2003 to 2013
$335.5M
Vascular endothelial cell integrins in angiogenesisP01CA081403 · NCI · CHILDREN'S HOSPITAL OF LOS ANGELES · PI SEEGER, ROBERT CHARLES · 2000 to 2014
$28.5M
Tumor microenvironment-dependent therapy resistanceP01CA217959 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI JOHN M MARIS · 2017 to 2026
$20.7M
Training Physician Scientists in Pediatric OncologyT32CA009659 · NCI · CHILDREN'S HOSPITAL OF LOS ANGELES · PI DECLERCK, YVES A · 1991 to 2020
$2.2M
Role of microRNAs released by Tumor Associated Macrophages within Exosomes in the chemoresistance of NeuroblastomaR01CA215753 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI FABBRI, MULLER · 2017 to 2021
$1.7M
Clinical Significance and Mechanism of Action of Exosomal microRNAs in Neuroblastoma chemoresistanceR01CA219024 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI FABBRI, MULLER · 2018 to 2022
$1.7M
NCI NIH HHS P01 CA081403NCI NIH HHS P01 CA217959NCI NIH HHS R01 CA215753NCI NIH HHS R01 CA219024NCI NIH HHS T32 CA009659NCI NIH HHS U10 CA098543
6 · The paper itself

Abstract

Immune checkpoint therapy has resulted in minimal clinical response in many pediatric cancers. We sought to understand the influence of immune checkpoint inhibition using anti-PD-1 and anti-CTLA-4 antibodies individually, in combination, and after chemotherapy on immune responses in minimal and established murine neuroblastoma models. We also sought to understand the role of the tumor microenvironment (TME) and PD-L1 expression and their alteration post-chemotherapy in our models and human tissues. PD-L1 expression was enriched in human tumor-associated macrophages and up-regulated after chemotherapy. In a murine minimal disease model, single and dual immune checkpoint blockade promoted tumor rejection, improved survival, and established immune memory with long-term anti-tumor immunity against re-challenge. In an established tumor model, only dual immune checkpoint blockade showed efficacy. Interestingly, dual immune checkpoint therapy distinctly influenced adaptive and innate immune responses, with significant increase in CD8

Indexed as

NeuroblastomaProgrammed Cell Death 1 ReceptorAnimalsCD28 AntigensCD8-Positive T-LymphocytesHumansImmune Checkpoint InhibitorsMiceT-LymphocytesTumor MicroenvironmentCD28 AntigensImmune Checkpoint InhibitorsProgrammed Cell Death 1 Receptordual immune checkpoint therapyimmune checkpoint therapyneuroblastomatumor-associated macrophagestumor microenvironment

Identifiers

PMID33489468
PMCPMC7801125
OpenAlexW3119790798

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.